Organon & Co.
OGNOrganon & Co. (OGN) is a global healthcare company specializing in the development and commercialization of pharmaceutical and biosimilar products. It focuses on women’s health, reproductive rights, and other therapeutic areas, aiming to improve health outcomes through innovative medicines. The company was spun off from Merck & Co. in 2021 to concentrate on its dedicated portfolio of women’s health, biosimilars, and other biopharmaceuticals.
Dividend History
Investors can expect a dividend payout of $0.02 per share, scheduled to be distributed in 4 days on December 11, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 11, 2025 | $0.02 | 2025-11-20 | 2025-11-20 |
| September 11, 2025 | $0.02 | 2025-08-15 | 2025-08-15 |
| June 12, 2025 | $0.02 | 2025-05-12 | 2025-05-12 |
| March 13, 2025 | $0.28 | 2025-02-24 | 2025-02-24 |
| December 12, 2024 | $0.28 | 2024-11-12 | 2024-11-12 |
Dividends Summary
- Organon & Co. has issued 18 dividend payments over the past 4 years
- The most recent dividend was paid 87 days ago, on September 11, 2025
- The highest dividend payed out to investors during this period was $0.28 per share
- The average dividend paid during this period was $0.24 per share.
Company News
The global contraceptive devices market is projected to grow from $20 billion in 2024 to $33 billion by 2032, driven by increased awareness, technological innovations, and changing demographic trends.
Daré Bioscience reported a Q2 2025 loss with negative revenue, but demonstrated progress in women's health product pipeline, including Sildenafil Cream and Ovaprene, while managing tight liquidity through strategic partnerships and grant funding.
Organon has completed the acquisition of Dermavant Sciences, a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology, including the FDA-approved VTAMA® (tapinarof) cream for the treatment of plaque psoriasis.
Organon reported Q2 2024 revenue of $1.61 billion, down 0.1% year-over-year, and EPS of $1.12 compared to $1.31 a year ago. The company's performance was mixed compared to analyst estimates, with revenue missing expectations but EPS beating estimates.
